Clinical and Translational Oncology

, Volume 21, Issue 2, pp 213–219 | Cite as

The value of radical radiotherapy in the primary tumor of newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients

  • H. Shuang
  • J. Feng
  • C. Caineng
  • J. Qifeng
  • J. Tin
  • C. YuanyuanEmail author
  • C. XiaozhongEmail author
Research Article



To explore the efficacy and patterns of treatment failure of radical radiotherapy in newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients.


We included 39 newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients who received radical radiotherapy and chemotherapy in Zhejiang Cancer Hospital. Treatment and prognosis information were collected. The Kaplan–Meier methods and Cox proportional hazards models were used to calculate survival rates and analyze prognostic factors.


After a median follow-up time of 38 months, the 1-, 3-, and 5-year overall survival rates were 97, 70, and 57.9%, while the 1-, 3-, and 5-year progression-free survival rates were 87, 59, and 50.9%, respectively. Age, numbers of metastases lesions, cycles, and schemes of chemotherapy were independent prognostic factors of the overall survival. Patients with no more than three metastasis lesions had a higher survival rate than those with ≥ 3 metastatic lesions (P = 0.023). More than four cycles chemotherapy provide a higher survival rate than less than four cycles. Chemotherapy including docetaxel had a significantly survival advantages (P = 0.041).


Radical radiotherapy is important for newly diagnosed oligo-metastatic nasopharyngeal carcinoma patients, which can still achieve long-term survival after chemo-radiotherapy.


Nasopharyngeal neoplasms Radiotherapy Oligo-metastases Prognosis 



We would like to thank all patients, GPs, and nurses for their participation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Research involving human participants

The study was carried out according to the precepts of the Helsinki Declaration. The study protocol was reviewed by the Medical Ethics Committee of the Zhejiang Cancer Hospital and they concluded that approval by a Medical Ethics Committee was not obligatory for this study.

Informed consent

All participants provided written informed consent.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  2. 2.
    Chua Melvin L K. JTSW: nasopharyngeal carcinoma. Lancet. 2016;387:1012–24.CrossRefGoogle Scholar
  3. 3.
    Chan OSH, Ngan RKC. Individualized treatment in stage IVC nasopharyngeal carcinoma. Oral Oncol. 2014;50(9):791–7.CrossRefGoogle Scholar
  4. 4.
    Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.CrossRefGoogle Scholar
  5. 5.
    Rusthoven CG, Lanning RM, Jones BL, et al. Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017;124(1):139–46.CrossRefGoogle Scholar
  6. 6.
    Hu J, Kong L, Gao J, et al. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a SEER analysis. Sci Rep UK. 2017;7(1):721.CrossRefGoogle Scholar
  7. 7.
    Chen M, Jiang R, Guo L, et al. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis. Chin J Cancer. 2013;32(11):604–13.CrossRefGoogle Scholar
  8. 8.
    Lin S, Tham IW, Pan J, et al. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. Am J Clin Oncol. 2012;35(5):474–9.CrossRefGoogle Scholar
  9. 9.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.CrossRefGoogle Scholar
  10. 10.
    Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.CrossRefGoogle Scholar
  11. 11.
    Setton J, Wolden S, Caria N, et al. Definitive treatment of metastatic nasopharyngeal carcinoma: report of 5 cases with review of literature. Head Neck. 2012;34(5):753–7.CrossRefGoogle Scholar
  12. 12.
    Wang CL, Su SF, Ouyang WW, et al. Significance of three dimensional radical radiotherapy dose determined by organ-lesion combination for primary tumor of oligometastatic stage IV NSCLC: a reanalysis of PPRA-RTOG 003. Chin J Radiat Oncol. 2016;25(6):576–81.Google Scholar
  13. 13.
    Lan YH, Tian YM, Bai L, et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma. Chin J Radiat Oncol. 2015;4:421–6.Google Scholar
  14. 14.
    Pan C, He N, Zhao M, et al. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol. 2011;28(4):1349–55.CrossRefGoogle Scholar
  15. 15.
    Lee AW, Ma BB, Ng WT, et al. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–64.CrossRefGoogle Scholar
  16. 16.
    Zou X, You R, Liu H, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer. 2017;77:117–26.CrossRefGoogle Scholar
  17. 17.
    Jiang R, You R, Pei X, et al. Development of a ten-signature classifier using a support vector machine integrated approach to subdivide the M1 stage into M1a and M1b stages of nasopharyngeal carcinoma with synchronous metastases to better predict patients’ survival. Oncotarget. 2016;7(3):3645.CrossRefGoogle Scholar
  18. 18.
    Hu S, He X, Dong M, et al. Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis. Med Oncol. 2015;32(9):224.CrossRefGoogle Scholar
  19. 19.
    Zeng L, Tian YM, Huang Y, et al. Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors. PLoS ONE. 2014;9(9):e108070.CrossRefGoogle Scholar
  20. 20.
    Li W, Bai Y, Wu M, et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: propensity score matching analysis. Oncotarget. 2016;8:52132.Google Scholar
  21. 21.
    Tian YH, Zou WH, Xiao WW, et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival. Head Neck. 2016;38(8):1152–7.CrossRefGoogle Scholar
  22. 22.
    Lee V, Kwong D, Leung T, et al. Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma—how far have we achieved? Crit Rev Oncol Hematol. 2017;114:13–23.CrossRefGoogle Scholar
  23. 23.
    Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388(10054):1883–92.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyZhejiang Cancer Hospital, Zhejiang Province Key Laboratory of Radiation OncologyHangzhouPeople’s Republic of China

Personalised recommendations